Radiation Oncology: An Extraordinary Space in the New Home of The James
•
1 like•183 views
Read more from the OSUCCC – James about the extraordinary radiation oncology center in the new home of The James Cancer Hospital and Solove Research Institute.
Report
Share
Report
Share
Download to read offline
Recommended
звіт 2014 ігнатьєв
Звіт за результатами діяльності Регіонального центру міжнародних проектів і програм (одного з проектів "Інституту сталого розвитку") у 2014 р.
Associate accountant
In this file, you can ref interview thank you letter materials for associate accountant position such as associate accountant interview thank you letter samples, interview thank you letter tips, associate accountant interview questions, associate accountant resumes, associate accountant cover letter …
Upc
La Universidad Popular del Cesar tuvo su origen en 1976 cuando se transformó el Instituto Tecnológico Universitario del Cesar en una universidad de carácter nacional. El documento describe la historia de cómo surgió la idea de crear una institución de educación superior en el departamento del Cesar y los esfuerzos a lo largo de varios años para establecer el instituto y luego convertirlo en una universidad completa a través de una ley del Congreso de Colombia.
In Vitro ADMET Considerations for Drug Discovery and Lead Generation
This document provides an overview of in vitro ADMET (absorption, distribution, metabolism, excretion, toxicity) assays that are used during drug discovery and development. Key points:
- In vitro assays are designed to mimic what happens to a compound in vivo and provide early data on absorption, distribution, metabolic transformations, potential toxicity, and more.
- Common assays examine solubility, permeability, protein binding, metabolic stability, metabolism pathways, toxicity, and effects of transporters and drug-drug interactions.
- The data generated from these assays are used throughout the drug development process to inform compound selection, design better candidates, and identify liabilities early. Understanding a compound's properties helps optimize the likelihood of success
Recommended
звіт 2014 ігнатьєв
Звіт за результатами діяльності Регіонального центру міжнародних проектів і програм (одного з проектів "Інституту сталого розвитку") у 2014 р.
Associate accountant
In this file, you can ref interview thank you letter materials for associate accountant position such as associate accountant interview thank you letter samples, interview thank you letter tips, associate accountant interview questions, associate accountant resumes, associate accountant cover letter …
Upc
La Universidad Popular del Cesar tuvo su origen en 1976 cuando se transformó el Instituto Tecnológico Universitario del Cesar en una universidad de carácter nacional. El documento describe la historia de cómo surgió la idea de crear una institución de educación superior en el departamento del Cesar y los esfuerzos a lo largo de varios años para establecer el instituto y luego convertirlo en una universidad completa a través de una ley del Congreso de Colombia.
In Vitro ADMET Considerations for Drug Discovery and Lead Generation
This document provides an overview of in vitro ADMET (absorption, distribution, metabolism, excretion, toxicity) assays that are used during drug discovery and development. Key points:
- In vitro assays are designed to mimic what happens to a compound in vivo and provide early data on absorption, distribution, metabolic transformations, potential toxicity, and more.
- Common assays examine solubility, permeability, protein binding, metabolic stability, metabolism pathways, toxicity, and effects of transporters and drug-drug interactions.
- The data generated from these assays are used throughout the drug development process to inform compound selection, design better candidates, and identify liabilities early. Understanding a compound's properties helps optimize the likelihood of success
Cell-Based Ion Channel and Cardiac Safety Assays
This document discusses the use of cell-based ion channel and cardiac safety assays in drug development. It notes that ion channels are responsible for electrical activity in the heart and that drugs blocking the hERG channel can cause dangerous arrhythmias by prolonging the QT interval. The document outlines how screening for effects on hERG and other cardiac ion channels in vitro and in silico, along with evaluating QT prolongation in vivo, allows assessment of torsadogenic risk to help identify potentially dangerous drugs. It also discusses using cardiomyocytes to confirm electrophysiology data and evaluate multi-channel effects to comprehensively assess proarrhythmic risk.
In-Vivo Safety - Pre Ind Drug Development
The document discusses the drug development process from pre-clinical research through Investigational New Drug (IND) application. It outlines the typical studies required to evaluate safety and toxicity, identify target organs of toxicity, determine appropriate dosing for clinical trials, and communicate risks. These include pharmacology, pharmacokinetics, safety pharmacology, acute and repeat-dose toxicology studies in two animal species along with genetic toxicology assays. The goals are to estimate initial safe doses for clinical trials and identify parameters that can monitor toxicity. The process seeks to identify potentially safe compounds for human testing while eliminating those that may be unsafe.
The Path from Chemical Tool to Approvable Drug
PD0332991 is a highly selective CDK4/6 inhibitor that was optimized through a structure-activity relationship study. It demonstrated potent inhibition of CDK4 with little activity against other kinases. PD0332991 showed good oral bioavailability and pharmacokinetics in rats. In vivo studies found it inhibited tumor growth in breast and colon cancer models at well-tolerated doses through daily oral administration, establishing its potential as a cancer treatment.
Target Validation / Biochemical and Cellular Assay Development
Target validation and assay development are essential steps in the drug discovery process. This document discusses several approaches to target validation, including using genetic tools like CRISPR/Cas9 and RNAi to interrogate targets. It also provides an example of developing a cellular assay using patient-derived cells to validate a target for cystic fibrosis. Additionally, the document describes a case study where phenotypic screening was used to discover a small molecule that restores function of a mutant protein associated with Usher Syndrome type III.
Intro to Ohio State's Drug Development Bootcamp: Practical Aspects of Positio...
The Ohio State University's Drug Development Institute (DDI) aims to accelerate innovative cancer research and speed cures to patients. DDI bridges the gap between Ohio State's strengths in early discovery and clinical development. DDI identifies promising molecules and technologies, partners with companies, and manages projects through various stages including target validation, lead identification, lead optimization, pre-clinical candidate development, and phase I clinical trials. DDI's team has experience in molecular biology, medicinal chemistry, clinical pharmacology, and clinical development. The document outlines DDI's services and approach, and advertises a "Drug Development Bootcamp" event focused on practical aspects of positioning research.
Ohio State's ASH Review 2017 - Myeloproliferative Disorders
Katherine Walsh, MD
Assistant Professor of Clinical Internal Medicine
The Ohio State University Comprehensive Cancer Center -
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Ohio State's ASH Review 2017 - Blood and Marrow Transplantation
Basem M. William, MD, MRCP(UK), FACP
Assistant Professor of Internal Medicine
Blood and Marrow Transplant Program
The Ohio State University Comprehensive Cancer Center -
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Ohio State's ASH Review 2017 - Benign Hematology
Spero R. Cataland, MD
Professor of Clinical Internal Medicine
The Ohio State University Comprehensive Cancer Center -
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Ohio State's ASH Review 2017 - Update in Myeloma
Don M. Benson Jr., MD, PhD, FACP
Associate Professor of Medicine
Head of Translational Research
Division of Hematology
The Ohio State University Comprehensive Cancer Center -
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Surgical (or Non-Surgical) Managment of Thyroid Cancer in the Era of "Over-Di...
This document discusses the rising rates of thyroid cancer diagnosis and treatment in the United States, and strategies to address the issue of potential over-diagnosis and over-treatment. It notes that while new thyroid cancer cases have tripled in recent decades, mortality rates have remained stable, suggesting many of these additional diagnoses are indolent cancers that do not require aggressive treatment. The document advocates for more conservative surgical management and observation for small, low-risk cancers. It also proposes renaming some indolent cancers and limiting unnecessary imaging to help reduce over-treatment. While these approaches could help address the problem of over-diagnosis, challenges remain in differentiating cancers requiring treatment from those that can be safely observed.
Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...
This document summarizes genetic predisposition to papillary thyroid cancer. It discusses heritability estimates for various cancers including thyroid cancer. Attempts to identify predisposing genes through linkage analysis and next generation sequencing have had limited success due to genetic heterogeneity and overdiagnosis of thyroid cancer. Genome-wide association studies have identified several loci associated with small increased risks. Whole exome sequencing of families identified a potentially pathogenic variant in the SRRM2 gene segregating with disease in one family. Overall, most heritability is likely due to many common low-penetrance variants, though rare high-penetrance mutations also exist. Gene discoveries have had modest clinical impact to date.
Genetic Syndromes and Thyroid Cancer by Pamela Brock, MS, LGC
This document discusses genetic syndromes associated with non-medullary thyroid cancer. It begins by outlining the objectives of reviewing established genetic conditions, discussing new candidate genes, and exploring genetic testing options. It then provides details on several known genetic syndromes and their associated thyroid cancer risks, including Cowden syndrome, Familial adenomatous polyposis, Carney complex, and Werner syndrome. It also discusses emerging candidate genes like CHEK2, DICER1, and MUTYH and their potential links to thyroid cancer. The document concludes by noting the low yield of genetic testing in familial non-medullary thyroid cancer cases but provides strategies to identify higher risk families.
ASCO 2016 Review Neuro-oncology
This document summarizes key findings from the 2016 ASCO conference regarding neuro-oncology updates. It discusses several studies on treatments for glioblastoma, anaplastic gliomas, low-grade gliomas, and brain metastases. For newly diagnosed glioblastoma in elderly patients, short-course radiation alone was found inferior to temozolomide and short-course radiation. For recurrent glioblastoma, adding lomustine to bevacizumab did not provide a survival advantage. The document also reviews findings on adjuvant temozolomide for anaplastic gliomas without 1p/19q co-deletion and a study comparing surgery with stereotactic radiosurgery versus surgery with whole brain radiation for
Melanoma ASCO Review Update 2016
This document summarizes key findings from the 2016 American Society of Clinical Oncology (ASCO) annual meeting regarding melanoma. It discusses several studies evaluating immunotherapy approaches for metastatic melanoma, including:
1) A phase 3 study showing pembrolizumab alone had higher response rates and longer progression-free and overall survival than ipilimumab.
2) A phase 3 study demonstrating that the combination of nivolumab and ipilimumab had higher response rates and longer progression-free survival than either agent alone.
3) A phase 2 study suggesting nivolumab followed by ipilimumab may be better tolerated and more effective than the reverse sequence.
The document concludes combination immunotherapy is generally
ASCO Review 2016 Upper GI Cancers
This document summarizes an expert presentation on upper GI cancers. It discusses trials investigating optimal treatment approaches for resectable gastric and esophageal cancers, including the role of chemotherapy and radiation therapy. Novel immunotherapies and targeted agents for gastric cancer are also reviewed, such as the FAST trial combining chemotherapy with an anti-CLDN18 antibody. For pancreatic cancer, the ESPAC-4 trial found that adding capecitabine to gemcitabine improved survival compared to gemcitabine alone.
ASCO Review 2016 Colorectal Cancer
§ This study evaluated nivolumab in patients with metastatic squamous cell carcinoma of the anal canal (SCCA) who had progressed on at least one prior therapy.
§ Of the initial 12 patients treated with nivolumab, 9 patients (24.3%) had an objective response, meeting the threshold for expansion to additional patients.
§ The trial was then expanded to enroll 37 total patients. The overall response rate was 26.5% among evaluable patients, with 2 complete responses and 7 partial responses observed.
§ Nivolumab demonstrated promising antitumor activity in this heavily pretreated patient population with metastatic SCCA.
ASCO 2016 Breast Cancer Review
The document summarizes several presentations from the 2016 ASCO Annual Meeting related to breast cancer research:
1) The MA.17R study found that extending aromatase inhibitor therapy beyond 5 years reduced breast cancer recurrences by 34% compared to 5 years of treatment alone. No worsening of quality of life or new toxicities were observed.
2) The PALOMA-2 study showed that adding palbociclib to letrozole significantly prolonged progression-free survival compared to letrozole alone in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.
3) Results from the MONARCH 1 study found that abemaciclib, a
ASCO 2016 Thoracic Review
1) The document summarizes results from several studies presented at the 2016 ASCO conference related to thoracic cancers.
2) A study of adjuvant chemotherapy regimens for non-small cell lung cancer found no difference in outcomes between regimens containing vinorelbine, docetaxel, gemcitabine, or pemetrexed. Pemetrexed had less toxicity.
3) A trial of twice-daily vs once-daily radiation therapy for limited stage small cell lung cancer found no difference in overall survival between the arms.
ASCO Review 2016 Addressing Health Disparities
Addressing Health Disparities in Cancer Care: From the Bench to the Bedside and Beyond
By Darrell M. Gray, II, MD, MPH
Asco 2016 GU Review
This document summarizes several studies presented at the 2016 ASCO Genitourinary Cancers Symposium. It discusses trials on prostate cancer, including studies on initial chemotherapy, dosing of cabazitaxel, quality of life impacts, adjuvant therapy after prostate removal, and germline findings in castration-resistant prostate cancer. It also summarizes the PRINCE trial on intermittent vs continuous docetaxel in metastatic castration-resistant prostate cancer, noting the trial was underpowered. For bladder cancer, it discusses checkpoint inhibitor trials with durvalumab, nivolumab, and atezolizumab. It also notes associations between cisplatin sensitivity and DNA damage repair gene alterations. For
How to Control Your Asthma Tips by gokuldas hospital.
Respiratory issues like asthma are the most sensitive issue that is affecting millions worldwide. It hampers the daily activities leaving the body tired and breathless.
The key to a good grip on asthma is proper knowledge and management strategies. Understanding the patient-specific symptoms and carving out an effective treatment likewise is the best way to keep asthma under control.
District Residency Programme (DRP) for PGs in India.pptx
District Residency Programme (DRP) for PG in India
More Related Content
More from OSUCCC - James
Cell-Based Ion Channel and Cardiac Safety Assays
This document discusses the use of cell-based ion channel and cardiac safety assays in drug development. It notes that ion channels are responsible for electrical activity in the heart and that drugs blocking the hERG channel can cause dangerous arrhythmias by prolonging the QT interval. The document outlines how screening for effects on hERG and other cardiac ion channels in vitro and in silico, along with evaluating QT prolongation in vivo, allows assessment of torsadogenic risk to help identify potentially dangerous drugs. It also discusses using cardiomyocytes to confirm electrophysiology data and evaluate multi-channel effects to comprehensively assess proarrhythmic risk.
In-Vivo Safety - Pre Ind Drug Development
The document discusses the drug development process from pre-clinical research through Investigational New Drug (IND) application. It outlines the typical studies required to evaluate safety and toxicity, identify target organs of toxicity, determine appropriate dosing for clinical trials, and communicate risks. These include pharmacology, pharmacokinetics, safety pharmacology, acute and repeat-dose toxicology studies in two animal species along with genetic toxicology assays. The goals are to estimate initial safe doses for clinical trials and identify parameters that can monitor toxicity. The process seeks to identify potentially safe compounds for human testing while eliminating those that may be unsafe.
The Path from Chemical Tool to Approvable Drug
PD0332991 is a highly selective CDK4/6 inhibitor that was optimized through a structure-activity relationship study. It demonstrated potent inhibition of CDK4 with little activity against other kinases. PD0332991 showed good oral bioavailability and pharmacokinetics in rats. In vivo studies found it inhibited tumor growth in breast and colon cancer models at well-tolerated doses through daily oral administration, establishing its potential as a cancer treatment.
Target Validation / Biochemical and Cellular Assay Development
Target validation and assay development are essential steps in the drug discovery process. This document discusses several approaches to target validation, including using genetic tools like CRISPR/Cas9 and RNAi to interrogate targets. It also provides an example of developing a cellular assay using patient-derived cells to validate a target for cystic fibrosis. Additionally, the document describes a case study where phenotypic screening was used to discover a small molecule that restores function of a mutant protein associated with Usher Syndrome type III.
Intro to Ohio State's Drug Development Bootcamp: Practical Aspects of Positio...
The Ohio State University's Drug Development Institute (DDI) aims to accelerate innovative cancer research and speed cures to patients. DDI bridges the gap between Ohio State's strengths in early discovery and clinical development. DDI identifies promising molecules and technologies, partners with companies, and manages projects through various stages including target validation, lead identification, lead optimization, pre-clinical candidate development, and phase I clinical trials. DDI's team has experience in molecular biology, medicinal chemistry, clinical pharmacology, and clinical development. The document outlines DDI's services and approach, and advertises a "Drug Development Bootcamp" event focused on practical aspects of positioning research.
Ohio State's ASH Review 2017 - Myeloproliferative Disorders
Katherine Walsh, MD
Assistant Professor of Clinical Internal Medicine
The Ohio State University Comprehensive Cancer Center -
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Ohio State's ASH Review 2017 - Blood and Marrow Transplantation
Basem M. William, MD, MRCP(UK), FACP
Assistant Professor of Internal Medicine
Blood and Marrow Transplant Program
The Ohio State University Comprehensive Cancer Center -
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Ohio State's ASH Review 2017 - Benign Hematology
Spero R. Cataland, MD
Professor of Clinical Internal Medicine
The Ohio State University Comprehensive Cancer Center -
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Ohio State's ASH Review 2017 - Update in Myeloma
Don M. Benson Jr., MD, PhD, FACP
Associate Professor of Medicine
Head of Translational Research
Division of Hematology
The Ohio State University Comprehensive Cancer Center -
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Surgical (or Non-Surgical) Managment of Thyroid Cancer in the Era of "Over-Di...
This document discusses the rising rates of thyroid cancer diagnosis and treatment in the United States, and strategies to address the issue of potential over-diagnosis and over-treatment. It notes that while new thyroid cancer cases have tripled in recent decades, mortality rates have remained stable, suggesting many of these additional diagnoses are indolent cancers that do not require aggressive treatment. The document advocates for more conservative surgical management and observation for small, low-risk cancers. It also proposes renaming some indolent cancers and limiting unnecessary imaging to help reduce over-treatment. While these approaches could help address the problem of over-diagnosis, challenges remain in differentiating cancers requiring treatment from those that can be safely observed.
Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...
This document summarizes genetic predisposition to papillary thyroid cancer. It discusses heritability estimates for various cancers including thyroid cancer. Attempts to identify predisposing genes through linkage analysis and next generation sequencing have had limited success due to genetic heterogeneity and overdiagnosis of thyroid cancer. Genome-wide association studies have identified several loci associated with small increased risks. Whole exome sequencing of families identified a potentially pathogenic variant in the SRRM2 gene segregating with disease in one family. Overall, most heritability is likely due to many common low-penetrance variants, though rare high-penetrance mutations also exist. Gene discoveries have had modest clinical impact to date.
Genetic Syndromes and Thyroid Cancer by Pamela Brock, MS, LGC
This document discusses genetic syndromes associated with non-medullary thyroid cancer. It begins by outlining the objectives of reviewing established genetic conditions, discussing new candidate genes, and exploring genetic testing options. It then provides details on several known genetic syndromes and their associated thyroid cancer risks, including Cowden syndrome, Familial adenomatous polyposis, Carney complex, and Werner syndrome. It also discusses emerging candidate genes like CHEK2, DICER1, and MUTYH and their potential links to thyroid cancer. The document concludes by noting the low yield of genetic testing in familial non-medullary thyroid cancer cases but provides strategies to identify higher risk families.
ASCO 2016 Review Neuro-oncology
This document summarizes key findings from the 2016 ASCO conference regarding neuro-oncology updates. It discusses several studies on treatments for glioblastoma, anaplastic gliomas, low-grade gliomas, and brain metastases. For newly diagnosed glioblastoma in elderly patients, short-course radiation alone was found inferior to temozolomide and short-course radiation. For recurrent glioblastoma, adding lomustine to bevacizumab did not provide a survival advantage. The document also reviews findings on adjuvant temozolomide for anaplastic gliomas without 1p/19q co-deletion and a study comparing surgery with stereotactic radiosurgery versus surgery with whole brain radiation for
Melanoma ASCO Review Update 2016
This document summarizes key findings from the 2016 American Society of Clinical Oncology (ASCO) annual meeting regarding melanoma. It discusses several studies evaluating immunotherapy approaches for metastatic melanoma, including:
1) A phase 3 study showing pembrolizumab alone had higher response rates and longer progression-free and overall survival than ipilimumab.
2) A phase 3 study demonstrating that the combination of nivolumab and ipilimumab had higher response rates and longer progression-free survival than either agent alone.
3) A phase 2 study suggesting nivolumab followed by ipilimumab may be better tolerated and more effective than the reverse sequence.
The document concludes combination immunotherapy is generally
ASCO Review 2016 Upper GI Cancers
This document summarizes an expert presentation on upper GI cancers. It discusses trials investigating optimal treatment approaches for resectable gastric and esophageal cancers, including the role of chemotherapy and radiation therapy. Novel immunotherapies and targeted agents for gastric cancer are also reviewed, such as the FAST trial combining chemotherapy with an anti-CLDN18 antibody. For pancreatic cancer, the ESPAC-4 trial found that adding capecitabine to gemcitabine improved survival compared to gemcitabine alone.
ASCO Review 2016 Colorectal Cancer
§ This study evaluated nivolumab in patients with metastatic squamous cell carcinoma of the anal canal (SCCA) who had progressed on at least one prior therapy.
§ Of the initial 12 patients treated with nivolumab, 9 patients (24.3%) had an objective response, meeting the threshold for expansion to additional patients.
§ The trial was then expanded to enroll 37 total patients. The overall response rate was 26.5% among evaluable patients, with 2 complete responses and 7 partial responses observed.
§ Nivolumab demonstrated promising antitumor activity in this heavily pretreated patient population with metastatic SCCA.
ASCO 2016 Breast Cancer Review
The document summarizes several presentations from the 2016 ASCO Annual Meeting related to breast cancer research:
1) The MA.17R study found that extending aromatase inhibitor therapy beyond 5 years reduced breast cancer recurrences by 34% compared to 5 years of treatment alone. No worsening of quality of life or new toxicities were observed.
2) The PALOMA-2 study showed that adding palbociclib to letrozole significantly prolonged progression-free survival compared to letrozole alone in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.
3) Results from the MONARCH 1 study found that abemaciclib, a
ASCO 2016 Thoracic Review
1) The document summarizes results from several studies presented at the 2016 ASCO conference related to thoracic cancers.
2) A study of adjuvant chemotherapy regimens for non-small cell lung cancer found no difference in outcomes between regimens containing vinorelbine, docetaxel, gemcitabine, or pemetrexed. Pemetrexed had less toxicity.
3) A trial of twice-daily vs once-daily radiation therapy for limited stage small cell lung cancer found no difference in overall survival between the arms.
ASCO Review 2016 Addressing Health Disparities
Addressing Health Disparities in Cancer Care: From the Bench to the Bedside and Beyond
By Darrell M. Gray, II, MD, MPH
Asco 2016 GU Review
This document summarizes several studies presented at the 2016 ASCO Genitourinary Cancers Symposium. It discusses trials on prostate cancer, including studies on initial chemotherapy, dosing of cabazitaxel, quality of life impacts, adjuvant therapy after prostate removal, and germline findings in castration-resistant prostate cancer. It also summarizes the PRINCE trial on intermittent vs continuous docetaxel in metastatic castration-resistant prostate cancer, noting the trial was underpowered. For bladder cancer, it discusses checkpoint inhibitor trials with durvalumab, nivolumab, and atezolizumab. It also notes associations between cisplatin sensitivity and DNA damage repair gene alterations. For
More from OSUCCC - James (20)
Target Validation / Biochemical and Cellular Assay Development
Target Validation / Biochemical and Cellular Assay Development
Intro to Ohio State's Drug Development Bootcamp: Practical Aspects of Positio...
Intro to Ohio State's Drug Development Bootcamp: Practical Aspects of Positio...
Ohio State's ASH Review 2017 - Myeloproliferative Disorders
Ohio State's ASH Review 2017 - Myeloproliferative Disorders
Ohio State's ASH Review 2017 - Blood and Marrow Transplantation
Ohio State's ASH Review 2017 - Blood and Marrow Transplantation
Surgical (or Non-Surgical) Managment of Thyroid Cancer in the Era of "Over-Di...
Surgical (or Non-Surgical) Managment of Thyroid Cancer in the Era of "Over-Di...
Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...
Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...
Genetic Syndromes and Thyroid Cancer by Pamela Brock, MS, LGC
Genetic Syndromes and Thyroid Cancer by Pamela Brock, MS, LGC
Recently uploaded
How to Control Your Asthma Tips by gokuldas hospital.
Respiratory issues like asthma are the most sensitive issue that is affecting millions worldwide. It hampers the daily activities leaving the body tired and breathless.
The key to a good grip on asthma is proper knowledge and management strategies. Understanding the patient-specific symptoms and carving out an effective treatment likewise is the best way to keep asthma under control.
District Residency Programme (DRP) for PGs in India.pptx
District Residency Programme (DRP) for PG in India
Debunking Nutrition Myths: Separating Fact from Fiction"
In a world overflowing with diet trends and conflicting nutrition advice, it’s easy to get lost in misinformation. This article cuts through the noise to debunk common nutrition myths that may be sabotaging your health goals. From the truth about carbohydrates and fats to the real effects of sugar and artificial sweeteners, we break down what science actually says. Equip yourself with knowledge to make informed decisions about your diet, and learn how to navigate the complexities of modern nutrition with confidence. Say goodbye to food confusion and hello to a healthier you!
KENT'S REPERTORY by dr niranjan mohanty.pptx
its a presentation on Dr kents Repertory by Dr niranjan Mohanty
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montrealRESPIRATORY DISEASES by bhavya kelavadiya
The Children are very vulnerable to get affected with respiratory disease.
In our country, the respiratory Disease conditions are consider as major cause for mortality and Morbidity in Child.
Top Travel Vaccinations in Manchester
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
biomechanics of running. Dr.dhwani.pptx
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
Public Health Lecture 4 Social Sciences and Public Health
Sociology, Anthropology and Psychology as applied to Public Health
Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
Breast cancer: Post menopausal endocrine therapy
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Fallopian tube blockage may cause female infertility. For treatment, herbal medicine Fuyan Pill can be a solution.
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
This document outlines policies and procedures for handling narcotic and controlled drugs in NABH accredited hospitals.
How to choose the best dermatologists in Indore.
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
une 2024 Oncology Cartoons By Dr Kanhu Charan Patro
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...ayushrajshrivastava7
Regulatory Affairs
Full hand written notes
M.pharm - 1st year .Recently uploaded (20)
How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.
District Residency Programme (DRP) for PGs in India.pptx
District Residency Programme (DRP) for PGs in India.pptx
Debunking Nutrition Myths: Separating Fact from Fiction"
Debunking Nutrition Myths: Separating Fact from Fiction"
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
Public Health Lecture 4 Social Sciences and Public Health
Public Health Lecture 4 Social Sciences and Public Health
Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy in Ayurveda - Classical Categorization and Synonyms
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Radiation Oncology: An Extraordinary Space in the New Home of The James
- 1. Radiation Oncology: An Extraordinary Space in the New Home of The James jamesline.com /radiation-oncology-extraordinary-space-new-home-james/ July 31, 2014 3:57 pm Radiation oncology is one of the most extraordinary spaces in the new home of The James Cancer Hospital and Solove Research Institute. There is no routine cancer, and the new James is no routine cancer hospital. “The mere fact that we’re on the second floor of the new James speaks volumes about the uniqueness of our radiation oncology center,” says Arnab Chakravarti, MD, chair of the department of radiation oncology at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James). “Because radiation oncology vaults and equipment are so heavy, most radiation oncology departments are located in the basements of hospitals and medical centers.” “Our extensive experience dictates that cancer patients often feel depressed by the lack of sunlight,” Chakravarti adds. “In our new space, sunshine pours through the windows, and the bright cheerful ambiance creates a very therapeutic and healing environment for our cancer patients.” Furthermore, cancer care and treatment in the new James is not a “one-size-fits-all” approach. “There are no routine types of cancer,” says Chakravarti. “That’s why it’s so important to personalize care for the individual patient.” At the OSUCCC – James, physicians work to treat the whole patient and not just the disease with multidisciplinary teams of radiation, medical and surgical oncologists, holding weekly meetings to discuss each patient’s case in detail and tailor a treatment plan. “That’s one of the reasons why I think we deliver the best care in the world,” Chakravarti says. For more updates about the new James and the cancer care and treatment offered here, subscribe to the OSUCCC – James Blog.